Assessing the effect of Imeglimin in Type 2 Diabetes

INTERVENTION: Intervention1: Imeglimin: Imeglimin is the first medication of a novel class of oral antidiabetic medications known as glimins. Unlike conventional glucose‐lowering medications, imeglimin has a unique method of action that increases peripheral tissue insulin sensitivity and increases insulin secretion because glucose stimulates pancreatic beta cells. Control Intervention1: Standard Care of treatment: Standard Care of treatment CONDITION: Health Condition 1: E119‐ Type 2 diabetes mellitus without complications PRIMARY OUTCOME: To evaluate the effect of Imeglimin 1000 mg on glycemic parameters by assessing changes in HbA1c, MAGE, TIR, TAR, TBR, and glycemic variability from baseline to Final.Timepoint: 6 months SECONDARY OUTCOME: To assess the efficacy of the Imeglimin 1000 mg by evaluating changes from baseline to final in HOMA IR, Homa beta, FBG, PPG, C‐Peptide Assay. ; To evaluate the safety of the Imeglimin 1000 mg by assessing the incidence of the AEs or SAEsTimepoint: 6 months INCLUSION CRITERIA: Age greater that or equal to 18 years HbA1c greater that or equal to 7.5 to 10.5 T2DM Duration greater than 6 months Patients experiencing inadequate glycaemic control on lesser than or equal to 2 OADs Willing to use CGM device